Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
Grapiprant is a selective antagonist for prostaglandin E PGE
2019-11-07
Grapiprant () is a selective antagonist for prostaglandin E (PGE) receptor subtype 4 (EP4) identified as a clinical candidate for the treatment of inflammatory pain associated with osteoarthritis (OA). It is currently under development for use in humans and dogs. The projected dosing regimen of grap
-
Although MMP might be a
2019-11-07
Although MMP-9 might be a downstream target of Src kinase signaling (Liu and Sharp, 2011), a direct connection has not been established. We showed for the first time that, in the collagenase-induced ICH model, Src kinase signaling regulates MMP-9 activity and mediates EP1R toxicity. Consistent with
-
The cpm corresponding to bound substrate in the sample well
2019-11-07
The cpm corresponding to bound substrate in the sample well can be expressed as the difference between the total cpm in the sample well (3Hswtotal; 14Cswtotal) and the cpm for the unbound substrate in the sample well, as illustrated by Eq. (2): By combining Eqs. (1), (2), cpm for the bound substrat
-
Tasquinimod More unusual modifications also regulate DUBs Re
2019-11-07
More unusual modifications also regulate DUBs. Recent reports have illustrated how reactive oxygen species (ROS) can regulate DUB activity 87, 88, 89, 90. ROS can serve as potent signaling molecules by reacting with active site cysteines of tyrosine phosphatases and some cysteine peptidases to form
-
br Limitations There are some limitations to take into accou
2019-11-07
Limitations There are some limitations to take into account when interpreting these results. Firstly, direct causation cannot be established in this cross-sectional study, and it may be the downstream effects of TNFα, such as increased Embelin production, which are more proximally related to cog
-
br Materials and methods br Data and
2019-11-07
Materials and methods Data and statistical analysis The results were expressed as mean ± SEM. One-way analysis of variance (ANOVA), followed by Bonferroni\'s post-test or unpaired Student\'s t-test were used to determine significant differences between groups. The program used for statistical
-
The upregulation of PTGS and PTGS
2019-11-07
The upregulation of PTGS1 and PTGS2 in late gestation in mares could be linked to the high levels of estrogens produced by the fetoplacental unit. Estrogens are thought to be effective stimulators of prostaglandin production by potentially up regulating PTGS2 expression. Although a recent publicatio
-
br Discussion We are reporting a
2019-11-07
Discussion We are reporting a cryptic insertion of chromosome 22 material (EWS) to the long arm of chromosome 11 (11q24, FLI-1) recognizable by FISH in FDA-approved Drug Library exhibiting trisomy 8 as the sole cytogenetic anomaly. In ES and PNET tumors, trisomy 8 is the most common secondary ab
-
To our knowledge immunohistochemical analysis for proGRP
2019-11-07
To our knowledge, immunohistochemical analysis for proGRP was done in 5 cases [9], [10], [17], [18]. Takagi-Takahashi et al. reported that the tumor depsipeptide were positive for proGRP in one case [9]. Yamaguchi et al. also showed that tumor cells in two patients of ES/PNET with elevated serum pr
-
br Genotype phenotype correlations Genotype
2019-11-06
Genotype-phenotype correlations Genotype-phenotype correlations are limited. Compared with individuals with truncating variants, those with pathogenic missense variants in the adenosine triphosphate binding site had a milder disorder, some with ability to walk unaided, better hand use, and less r
-
Enolase is an example of a moonlighting
2019-11-06
Enolase is an example of a moonlighting protein that displays multiple biological actions, including plasminogen, laminin, fibronectin, mucin and cytokeratin binding properties. It has also been described as a complement-evasion protein and as a protein capable of inducing neutrophil trap formation.
-
Several molecular differences between visceral and subcutane
2019-11-06
Several molecular differences between visceral and subcutaneous adipose tissue have been described. One of the most demarcating differences between adipose depots is the signature of developmental genes, including Hox, Shox, and T-box genes [12], [13]. Lineage tracing studies have revealed key devel
-
br Acknowledgments br Introduction Inflammation is the prote
2019-11-06
Acknowledgments Introduction Inflammation is the protective reaction of the body to infection, injury, or irritation with the aim to remove harmful stimuli such as pathogens, damaged cells, or allergic irritants and to initiate the healing process. Inflammatory abnormalities play a crucial rol
-
The totality of evidence from randomized clinical trials sup
2019-11-06
The totality of evidence from randomized clinical trials supports the premise that worsening ezh2 inhibitor australia failure is a class effect of DPP-4 inhibitors. A meta-analysis by Verma et al. (54) of 100 randomized controlled clinical trials reported that the use of DPP-4 inhibitors was accomp
-
The CPA parameters of SO were calculated based on Eq
2019-11-06
The CPA parameters of SO2 were calculated based on Eq. (11) using the vapor pressure and saturated liquid density data of SO2 over the reduced temperature range of 0.55 to 0.9. All of the data used were taken from the NIST database [53]. The resulting CPA parameters of SO2 are presented in Table S1
14912 records 887/995 page Previous Next First page 上5页 886887888889890 下5页 Last page